CBD, Curcumin, Omega-3, Vitamins and Minerals: A Formula Guide
By Provitura Editorial Team
Updated
- Ingredients
- Provitura
- Nutrition
Formula content should avoid synergy promises
A formula guide can explain why ingredients are included, but it should not claim that CBD, curcumin, omega-3, vitamins and minerals create a proven combined effect. The word synergy is especially risky when it suggests outcomes that have not been demonstrated for the finished product.
Separate authorised nutrients from other ingredients
Some vitamins and minerals have authorised EU health claims when a product meets the relevant conditions. CBD, curcumin and piperine should be handled differently: describe their presence and role in the formula without borrowing nutrient claims or presenting them as treatment ingredients.
How to read a multi-ingredient label
Check the daily serving, the amount of each ingredient, whether the claims match authorised wording and whether the product duplicates something you already take. People using medication should also consider interaction questions because several ingredients in one capsule can make a routine harder to assess.
Provitura framing
For Provitura, the useful focus is transparency: what is in the capsule, how the serving is structured and where evidence limits apply. EFSA's 2026 cannabidiol statement creates an important regulatory discrepancy for formula copy: the published Provitura label facts describe Light, Medium and Strong daily CBD amounts, while EFSA's provisional intake level is 0.0275 mg per kg body weight per day, roughly 2 mg per day for a 70 kg adult. EFSA limits that conclusion to specified formulations with at least 98% pure CBD plus other conditions, so the figure must not be presented as a Provitura dose recommendation, legal limit or safety proof.
How to avoid formula overclaiming
Multi-ingredient formulas are easy to overstate because each ingredient brings its own associations. Curcumin, omega-3, vitamins, minerals and CBD should not be blended into one broad promise unless the finished product claim is properly supported. EU copy should identify which statements are authorised nutrient claims, which are product facts and which are unresolved CBD questions.
The current EFSA CBD statement makes that separation more important, not less. The provisional level is narrow and conditional, while the Provitura label facts describe higher CBD amounts per daily serving. That discrepancy should remain clearly visible as an unresolved regulatory issue. It should not be softened into a recommendation, and it should not be used as reassurance.